Comparative Pharmacology
Head-to-head clinical analysis: BEEPEN VK versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEEPEN VK versus V CILLIN K.
BEEPEN-VK vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V potassium is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This disrupts the cross-linking of peptidoglycan chains, leading to cell lysis and death. It is bactericidal against susceptible organisms.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections; maximum 4 g/day.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is 0.7-1.4 hours in patients with normal renal function; prolonged to 3-20 hours in severe renal impairment (CrCl <10 mL/min).
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Primarily renal (70-80% as unchanged drug), with minor biliary/fecal excretion. Renal clearance is via tubular secretion and glomerular filtration.
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic